Polymorphs of brimonidine pamoate

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,637,515
App. No.: 13/826,516
Granted: Jan 28, 2014
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

A polymorph of brimonidine pamoate having the formula exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

Claims (5)

1. A brimonidine pamoate polymorph exhibiting an X-ray powder diffraction spectrum comprising peaks at 2θ angles of 9.7°, 14.6°, 25.9° and 26.5°±0.2°.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a brimonidine pamoate polymorph of claim 1 .

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises an aqueous medium.

4. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises an organic medium.

5. A method for producing the brimonidine pamoate polymorph of claim 1 , said method comprising: contacting a brimonidine pamoate polymorph that exhibits an X-ray powder diffraction spectrum comprising peaks at 2θangles of 13.5°, 20.6°, 21.1° and 24.4°±0.2°, with (i) water, or (ii) a mixture of N,N-dimethylformamide and water.

Assignments (21)

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED

Reel/Frame 073637/0001 →

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.

Reel/Frame 073637/0126 →

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.

Reel/Frame 073654/0242 →

ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025

From: CITIBANK, N.A., AS RESIGNING AGENT

To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT

Reel/Frame 072469/0091 →

PATENT SECURITY AGREEMENT Recorded Jul 1, 2025

From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED

To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT

Reel/Frame 071773/0871 →

RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025

From: BARCLAYS BANK PLC, AS COLLATERAL AGENT

To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.

Reel/Frame 070778/0199 →

PATENT SECURITY AGREEMENT Recorded Oct 4, 2023

From: BAUSCH & LOMB INCORPORATED

To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT

Reel/Frame 065120/0086 →

OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022